Tsumura Toukisyakuyakusan :42 sachets (for two weeks)
|Manufacturer||TSUMURA & CO.|
|Brand||TSUMURA & CO.|
|Shipping Schedule||about 3 weeks after payment|
Tokishakuyakusan is indicated for the relief of the following symptoms of those patients who have generally weak muscles and are easily fatigued and whose waist and lower limbs are susceptible to cold:Anemia, malaise, climacteric disturbance (dull headache, headache, dizziness, shoulder stiffness, etc.), menstrual irregularity,dysmenorrhea, infertility, palpitation pounding, chronic nephritis, diseases during pregnancy (edema, habitual abortion, hemorrhoids, abdominal pain), beriberi, hemiplegia and valvular diseases of the heart
Light grayish brown Granules
7.5 g (3sachets for 1day) of TSUMURA Tokishakuyakusan extract granules contains 4.0 g of a dried extract of the following mixed crude drugs.JP Peony Root 4.0 gJP Atractylodes Lancea Rhizome 4.0 gJP Alisma Rhizome 4.0 gJP Poria Sclerotium 4.0 gJP Cnidium Rhizome 3.0 gJP Japanese Angelica Root 3.0 g(JP : The Japanese Pharmacopoeia)
Infertility (prevention of miscarriage)
The usual adult dose is 7.5 g/day orally in 2 or 3 divided doses before or between meals. The dosage may be adjusted according to the patient's age and body weight, and symptoms.
Careful Administration (TJ-23 should be administered with care in the following patients.) (1) Patients with an extremely weak gastrointestinal tract [Anorexia, epigastric distress, nausea, vomiting, abdominal pain, diarrhea, etc. may occur.] (2) Patients with anorexia, nausea or vomiting [These symptoms may be aggravated.]
Important Precautions (1) When TJ-23 is used, the patient’s “SHO” (constitution/symptoms) should be taken into account. The patient’s progress should be carefully monitored, and if no improvement in symptoms/findings is observed, continuous treatment should be avoided. (2) When TJ-23 is coadministered with other Kampo-preparations (Japanese traditional herbal medicines), etc., attention should be paid to the duplication of the contained crude drugs.
TJ-23 has not been investigated (drug use investigations, etc.) to determine the incidence of adverse reactions. Therefore, the incidence of adverse reactions is not known.